Equity-free startup acceleration to scale business, extend network and create global impact
We have been working on developing industrial vertical startup accelerators with the ambition of creating a national and international innovation platform to provide tangible solutions. As a not-for-profit foundation, we support high-potential startups and innovation projects operating in specific industrial sectors. Our acceleration models are built on fostering interactions between startup, SMBs and corporates and leveraging the resources and networks that we have access to in Switzerland and abroad.
Tech4Trust - season 6
For start-ups building the future of digital trust and cybersecurity
Starting on October 2024 until April 2025
6-month program
Applications for Season 7 will open in May 2025
This six-month Tech4Trust program is specifically geared to startups working in the fields of digital trust and cyber security. The aim is to get these businesses market-ready and revved-up for rapid but sustainable growth. It offers assistance to secure funding, start pilots and future-proof operations through first-class coaching, access to a wide network of industry experts, tailored workshops and informative events.
Tech4Regen - season 2
For startups addressing critical environmental and climate challenges
Starting March 2025
8-month program
Application deadline February 17, 2025
Tech4Regen is an acceleration program by EPFL Innovation Park addressing the breaches in planetary boundaries that threaten our economy. It identifies and supports disruptive startups and solutions through industrialization and business coaching, pilot projects, and international partnerships to enable large-scale deployment. The program fosters collaboration across scientific, financial, and business sectors to advance the transition to a regenerative economy.
Tech4Eva - season 5
For early stage to scale-up companies developing solutions for women's health
Starting Spring 2025
6-month program
Application closed
This global equity free acceleration program has been developed by the FemTech community especially for companies pushing the boundaries on technology relating to women’s health. The program’s team of industry experts will help them refine their business models, reveal the best marketing and business strategies and provide opportunities to meet potential investors and customers through its global reach.
Future of Health - season 6
For early-stage startups developing solutions in digital health
Starting March 2025
3 to 12-month program
Application deadline January 31, 2025
The Future of Health Grant provides an extensive support package designed to propel the success of early-stage digital health startups. This encompassing initiative includes up to CHF 90,000 in non-dilutive funding, personalized coaching, on-demand CxO services to enhance team capabilities, and invaluable market feedback sourced from a network of healthcare professionals.
· About our programs ·
About our programs
About our programs · About our programs · About our programs ·
Active network of leading corporate partners
Get active fundraising support during the program
International development
Tech4Eva is an amazing platform that allows to build strategic partnerships and to create a strong network with decision makers. The program has given us a huge visibility since the very early days. Thanks to Tech4Eva, b-rayZ was able to close its fundraising round of CHF4 Million during the 2022 program.
Cristina Rossi
CEO at b-rayZ
They've completed our programs
EmbrLabs - USA
By 2025, there will be 1.1 BN women in menopause, suffering from hotflashes. EmbrLabs has harnessed the body’s response to temperature via a wrist-worn bracelet to dramatically affect the impact of menopause symptoms. Embr Labs closed a B-round of 22million during the Tech4Eva program in 2021 and has received great international media coverage validating their product technology.
Muvon Therapeutics - Switzerland
A biotech spin-off from UZH with the mission to advance cell therapies for skeletal muscle regeneration, with the first indication: female stress urinary incontinence. The team is now fundraising 25million to develop further and start thir Phase II clinical trial and was also recently featured on the Top 30 In vivo’s 2022 Rising Leaders.
